Centessa Pharmaceuticals PLC ADR CNTA 深 沪
等待开盘 05-12 09:30:00 美东时间
39.585
+0.010
+0.03%
华盛通- 最 高39.75
- 今 开39.57
- 成交量 15.29万股
- 最 低 39.52
- 昨 收 39.575
- 总市值 372.26万
- 52周最高 40.26
- 市盈率 静 --
- 换手率 162.60%
- 52周最低 10.95
- 委 比 65.53%
- 总股本 9.40万
- 历史最高 40.26
- 量 比 0.38
- 振 幅 0.58%
- 历史最低 1.10
- 每 手 1
- 风险率 7.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium
Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.
04-01 22:43
Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook
US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.2%, while utilities fall 0.7%. FactSet reports upbeat Q2 results and raises outlook.
04-01 00:07
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
03-31 22:48
Needham Downgrades Centessa Pharmaceuticals to Hold
Needham analyst Ami Fadia downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Buy to Hold.
03-31 20:28
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Centessa Pharmaceuticals received FDA clearance to initiate a Phase 1 clinical study of ORX142, a novel OX2R agonist for treating neurological and neurodegenerative disorders. The study will assess safety, tolerability, and pharmacokinetics in healthy volunteers, with early proof-of-concept data expected this year. ORX142 is part of the company's orexin franchise, alongside ORX750, which is in Phase 2a for narcolepsy and hypersomnia.
2025-06-16 13:00
行业首家，“易鑫”获评“AAA知名商标品牌”
近日，“2025品牌日商标品牌发展会议”在北京全国人大会议中心举行。会上，易鑫凭借强大的品牌影响力与科技创新等综合实力，荣获“AAA级知名商标品牌”。此次获...
2025-05-20 12:34
Centessa Pharmaceuticals Announces $150M Proposed Public Offering Of American Depositary Shares
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an
2024-09-12 04:05
BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $20
BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and raises the price target from $15 to $20.
2024-09-09 20:45
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation Of Non-Human Primate Data For ORX142 At Sleep Europe 2024
Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, an...
2024-08-27 20:13
